一种HIV-1 D亚型gp140包膜蛋白疫苗的首次I期临床试验：在所有研究参与者中诱导的免疫活性
First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.
作者信息
Hurwitz Julia L, Lockey Timothy D, Jones Bart, Freiden Pamela, Sealy Robert, Coleman John, Howlett Nanna, Branum Kristen, Slobod Karen S
机构信息
Department of Immunology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
出版信息
AIDS. 2008 Jan 2;22(1):149-51. doi: 10.1097/QAD.0b013e3282f174ed.
PMID:18090404
Abstract
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
摘要
为对抗HIV-1的多样性，我们正在研发一种多包膜疫苗（由DNA、痘苗病毒和蛋白质载体组成）。为实现这一目标，我们对EnvPro（一种用明矾配制的gp140蛋白）进行了I期临床试验。该疫苗耐受性良好，且在每位试验参与者体内均引发了免疫反应。
Zotero 插件